Clinical Trials

At Texas Heart Institute
Texas Heart Institute App Clinical Research
Current Clinical Trials


Texas Heart Institute researchers conduct clinical trials to test the safety and efficacy of potential new devices, techniques and therapies to treat patients suffering from various cardiovascular issues.

Contact Us

ACTIVE-3 TICO Trial (NCT04501978)

Therapeutics for Inpatients with COVID-19

ALIVE Trial (NCT02931240)

Clinical Study of the BioVentrix Revivent System for Treatment of Left Ventricular Aneurysms (ALIVE)

ANTHEM-HFrEF Pivotal Study (NCT03425422)

Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure with Reduced Ejection Fraction

DCM II TRIAL (NCT04476901)

A Phase IIB randomized, placebo-controlled, multicenter study of the comparative efficacy and safety of transendocardial injection of allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy NIDCM.

The EXACT Trial (NCT04125732)

Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment

The Global cVAD Study (NCT04136392)

The Global cVAD Study will utilize observational data of the ABIOMED, Inc. hemodynamic support devices in real-world settings to drive best practice usage patterns identified through study analysis, to serve as a tool to measure and improve the quality of patient care, and also serve as a resource for future research and regulatory filings.


Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

Heart FID (NCT03037931)

Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency

Houston HeartReach

The Houston HeartReach Registry is a community-wide registry research study that aims to make improvements in heart disease prevention, diagnosis, and treatment for all women to help identify trends in heart-health risks in a diverse population of women, develop future clinical trials, and recruit women for future research studies.

LESS-VT (NCT03490201)

A clinical investigation to demonstrate the safety and effectiveness of ventricular ablation therapy using the FlexAbility Sensor Enabled Ablation Catheter in patients with drug-refractory monomorphic ventricular tachycardia in whom ventricular tachycardia recurs despite antiarrhythmic drug therapy or when antiarrhythmic drugs are not tolerated or desired.

OPTIMIZE (NCT03190473)

The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study

PERFORMANCE II Study (NCT04201132)

An open label study to evaluate the safety and effectiveness of the Neuroguard IEP System for the treatment of carotid artery stenosis in patients at elevated risk for adverse events following carotid endarterectomy (CEA).


The PORTICO clinical trial is a prospective, multi-center, randomized, controlled clinical study, designed to evaluate the safety and effectiveness of the Portico Transcatheter Heart Valve and Delivery Systems via transfemoral and alternative delivery methods.

Relieve HF (NCT03499236)

Reducing Lung congestion symptoms using the V-wave shunt in Advanced Heart Failure.

Stem Cell Therapy vs Standard of Care in Cardiomyopathy (NCT02962661)

Randomized 3-Arm Trial with Standard of Care Alone vs either Intravenous Infusion or Transendocardial Injection of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) plus Standard of Care in Patients with Anthracycline-Associated Cardiomyopathy

TESICO (NCT04843761)

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with Acute Respiratory Distress Syndrome Associated with COVID-19


A randomized, controlled, multicenter, open-label trial that will study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have an increased LDL-cholesterol (≥70 mg/dL) despite being treated with a statin drug.